Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma

被引：1
|
作者：
Stewart, J. R. [1 ]
Baxter, J. [1 ]
Zatreanu, D. [1 ]
Brough, R. [1 ]
Song, F. [1 ]
Konde, A. [1 ]
Krastev, D. [1 ]
Alexander, J. [2 ]
Natrajan, R. [2 ]
Pettitt, S. [1 ]
Banerjee, S. [3 ]
Lord, C. [1 ]
机构：
[1] ICR Inst Canc Res, Chester Beatty Labs, Gene Funct & Breast Canc Res, London, England
[2] ICR Inst Canc Res, Chester Beatty Labs, Breast Canc Res, London, England
[3] Royal Marsden Hosp Chelsea, Gynaecol Dept, London, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3P
引用
收藏
页码：S383 / S384
页数：2
相关论文
共 50 条
  • [1] PPP2R1A missense mutations as a novel biomarker of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma
    Stewart, J.
    Baxter, J.
    Zatreanu, D.
    Brough, R.
    Song, F.
    Konde, A.
    Krastev, D.
    Alexander, J.
    Natrajan, R.
    Banerjee, S.
    Stephen, P.
    Lord, C.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S99 - S99
  • [2] Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC)
    Miller, R. E.
    Bajrami, I.
    Brough, R.
    Konde, A.
    Campbell, J.
    Rafiq, R.
    Ashworth, A.
    Lord, C. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 103 - 104
  • [3] ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies
    Caumanns, Joseph J.
    Wisman, G. Bea A.
    Berns, Katrien
    van der Zee, Ate G. J.
    de Jong, Steven
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (02): : 176 - 184
  • [4] ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component
    Nishikimi, Kyoko
    Kiyokawa, Takako
    Tate, Shinichi
    Iwamoto, Masami
    Shozu, Makio
    HISTOPATHOLOGY, 2015, 67 (06) : 866 - 871
  • [5] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    MODERN PATHOLOGY, 2011, 24 : 259A - 259A
  • [6] Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, Daichi
    Mao, Tsui-Lien
    Fukayama, Masashi
    Nakagawa, Shunsuke
    Yano, Tetsu
    Taketani, Yuji
    Shih, Ie-Ming
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2010, 11 (12): : 5121 - 5129
  • [7] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma.
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    LABORATORY INVESTIGATION, 2011, 91 : 259A - 259A
  • [8] The role of chromatin remodeler protein ARID1a in ovarian clear cell carcinoma
    Lakshminarasimhan, Ranjani
    Andreu-Vieyra, Claudia
    Lawrenson, Kate
    Gayther, Simon A.
    Jones, Peter A.
    Liang, Gangning
    CANCER RESEARCH, 2016, 76
  • [9] Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression
    Choi, Jae Yoon
    Han, Hyun Ho
    Kim, Young Tae
    Lee, Joo Hyun
    Kim, Baek Gil
    Kang, Suki
    Cho, Nam Hoon
    YONSEI MEDICAL JOURNAL, 2017, 58 (01) : 59 - 66
  • [10] ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
    Katrien Berns
    Joseph J. Caumanns
    E. Marielle Hijmans
    Annemiek M. C. Gennissen
    Tesa M. Severson
    Bastiaan Evers
    G. Bea A. Wisman
    Gert Jan Meersma
    Cor Lieftink
    Roderick L. Beijersbergen
    Hiroaki Itamochi
    Ate G. J. van der Zee
    Steven de Jong
    René Bernards
    Oncogene, 2018, 37 : 4611 - 4625
12345